| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 1,052 | 1,160 | 1,206 | 1,116 | 1,028 | 1,108 | 1,083 | 1,018 | 920 | 928 | 1,077 | 1,042 | 1,010 | 1,015 | 1,132 | 1,048 | 880 | 760 | 705 | 807 | 720 | 2,077 | 730 | 865 | 640 | 861 | 866 | 856 | 669 | 652 | 736 | 701 | 710 | 658 | 777 | 709 | 754 | 769 | 818 | 729 | 758 | 758 |
| Expenses | 943 | 973 | 1,031 | 1,001 | 945 | 1,016 | 964 | 995 | 1,028 | 1,309 | 1,001 | 959 | 1,024 | 1,003 | 1,058 | 1,064 | 827 | 726 | 670 | 656 | 674 | 1,298 | 697 | 706 | 698 | 739 | 765 | 742 | 871 | 611 | 831 | 657 | 771 | 642 | 681 | 664 | 803 | 648 | 699 | 593 | 679 | 763 |
| EBITDA | 109 | 187 | 175 | 116 | 83 | 92 | 119 | 23 | -108 | -381 | 76 | 84 | -15 | 12 | 74 | -16 | 53 | 34 | 35 | 151 | 47 | 779 | 33 | 159 | -58 | 122 | 101 | 114 | -202 | 41 | -95 | 44 | -61 | 16 | 96 | 45 | -49 | 121 | 119 | 136 | 79 | -5 |
| Operating Profit % | 13 % | 15 % | 16 % | 7 % | 6 % | 7 % | 9 % | 0 % | -19 % | -47 % | 2 % | 5 % | -1 % | 0 % | 6 % | -2 % | 4 % | -0 % | 2 % | 12 % | 2 % | -117 % | 2 % | 8 % | -10 % | 14 % | 11 % | 13 % | -33 % | -3 % | -22 % | 6 % | -14 % | 0 % | 10 % | 5 % | -15 % | 12 % | 14 % | 18 % | 9 % | -3 % |
| Depreciation | 34 | 35 | 35 | 36 | 37 | 36 | 37 | 38 | 37 | 37 | 36 | 38 | 38 | 39 | 40 | 41 | 45 | 55 | 53 | 56 | 61 | 56 | 57 | 68 | 65 | 64 | 61 | 62 | 59 | 64 | 65 | 66 | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 |
| Interest | 14 | 24 | 30 | 32 | 43 | 49 | 56 | 61 | 59 | 61 | 68 | 62 | 65 | 73 | 65 | 64 | 64 | 71 | 65 | 79 | 61 | 74 | 61 | 60 | 55 | 64 | 69 | 80 | 86 | 73 | 70 | 83 | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 |
| Profit Before Tax | 60 | 128 | 110 | 48 | 4 | 7 | 26 | -76 | -204 | -480 | -28 | -16 | -118 | -100 | -32 | -121 | -55 | -92 | -82 | 16 | -75 | 649 | -85 | 31 | -178 | -6 | -29 | -28 | -347 | -96 | -230 | -105 | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 |
| Tax | 27 | 30 | 12 | -22 | 17 | -9 | 1 | -16 | 3 | -17 | -19 | 27 | 35 | -5 | -1 | -44 | -41 | -55 | 12 | -3 | -144 | -111 | -88 | -1 | -71 | 1 | -66 | -30 | -36 | -21 | -23 | -3 | 44 | 18 | 38 | -1 | -3 | 10 | 7 | 1 | 23 | -1 |
| Net Profit | 33 | 98 | 98 | 69 | -13 | 17 | 25 | -60 | -207 | -463 | -9 | -43 | -153 | -95 | -31 | -77 | -14 | -37 | -94 | 19 | 69 | 760 | 3 | 32 | -107 | -7 | 37 | 2 | -311 | -75 | -207 | -102 | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 |
| EPS in ₹ | 3.10 | 8.36 | 8.37 | 6.52 | -0.49 | 1.44 | 2.25 | -4.88 | -15.81 | -37.06 | -0.80 | -3.69 | -13.97 | -7.79 | -2.06 | -6.42 | -2.62 | -4.06 | -7.42 | 0.87 | 4.36 | 68.64 | 0.32 | 1.38 | -8.38 | -1.15 | 2.79 | -0.61 | -21.20 | -4.64 | -13.15 | -6.62 | -14.37 | -9.28 | -5.37 | -5.75 | -11.64 | -0.95 | -1.47 | 0.91 | -1.57 | -5.53 |
Wockhardt
Wockhardt
1,460.00
-32.80
(-2.20%)
Market Cap
24,256.80 Cr
EPS
-3.02
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
1,868.80
52 Week Low
915.00
PB Ratio
5.58
Debt to Equity
0.57
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Wockhardt has filed a New Drug Application with the U.S. FDA for Zidebactam-Cefepime, a treatment intended for serious Gram-negative infections. The filing represents a regulatory milestone for the pharmaceutical company's drug development pipeline.
Wockhardt shares jumped over 9% to reach an intraday high of Rs 1,458, recovering from Friday's 10.2% decline. The rally followed White House clarification that countries with existing US trade deals will be exempted from pharma tariffs, facing only 15% duties instead of the announced 100% tariff on foreign-made branded drugs. This development benefits Wockhardt as its flagship antibiotic Zaynich will be produced in Europe, preserving the drug's launch economics. Zaynich targets a $7 billion market in the US and Europe, with a Rs 17,000 crore addressable market in India. The stock has gained almost 50% over the past 12 months.
Wockhardt stated that President Donald Trump's 100% tariff order on branded drugs will not disrupt its plans to launch antibiotic Zaynich in the United States. Chairman Habil F Khorakiwala explained that Zaynich is manufactured in Europe, not India, making it exempt from Indian tariffs. The company plans to file an FDA application for Zaynich next week. Khorakiwala noted that most of Wockhardt's new molecules are discovered in India but manufactured in Europe, reducing exposure to Indian-origin tariffs. He highlighted that 40% of medicines used in America come from India, suggesting major restrictions could raise US drug prices. Wockhardt expects to improve margins by at least 200 basis points and achieve double-digit revenue growth this year. The company has a market capitalization of ₹22,780 crore, with shares trading at ₹1,400 and gaining 40% over the past year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.20 | #1 3,92,579.20 | 34.22 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 55.14 | |
5,866.00 | 1,51,582.60 | 65.74 | 9,712.00 | 18.67 | 2,191 | 26.74 | 30.76 | |
1,517.70 | 1,22,213.20 | 22.68 | 28,409.50 | 7.12 | 5,291 | 9.88 | 42.86 | |
3,514.70 | 1,20,726.90 | 59.71 | 11,539.40 | 6.99 | 1,911 | 19.91 | 47.37 | |
1,248.10 | 1,03,884.40 | #1 18.31 | 33,741.20 | 16.73 | 5,725 | 1.26 | 41.85 | |
2,448.00 | 1,00,696.60 | 53.25 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 35.51 | |
988.30 | 99,732.90 | 21.41 | 23,511.00 | 18.55 | 4,615 | 2.60 | 43.75 | |
1,973.60 | 90,496.80 | 24.47 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 51.60 | |
5,442.00 | 65,276.50 | 28.71 | 13,458.30 | 3.70 | 2,216 | 21.39 | 55.81 | |
29,965.00 | 63,514.20 | 43.71 | 6,684.70 | 9.64 | 1,414 | 11.55 | 36.82 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
6.70 %
Net Income Growth
-87.92 %
Cash Flow Change
-110.05 %
ROE
-90.54 %
ROCE
-264.98 %
EBITDA Margin (Avg.)
249.88 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,939 | 8,121 | 9,022 | 8,162 | 7,844 | 8,179 | 7,774 | 8,243 | 7,683 | 7,649 | 8,135 |
| Fixed Assets | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 |
| Current Assets | 3,522 | 3,952 | 4,535 | 3,380 | 2,815 | 2,430 | 2,425 | 2,589 | 2,208 | 2,073 | 2,465 |
| Capital Work in Progress | 1,007 | 1,036 | 1,244 | 1,433 | 1,446 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 |
| Investments | 339 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 |
| Other Assets | 3,470 | 4,276 | 4,443 | 3,628 | 3,341 | 3,092 | 3,052 | 3,439 | 3,102 | 3,046 | 2,944 |
| Total Liabilities | 6,939 | 8,121 | 9,022 | 8,162 | 7,844 | 8,179 | 7,774 | 8,243 | 7,683 | 7,649 | 8,135 |
| Current Liabilities | 1,773 | 1,842 | 1,979 | 2,692 | 2,864 | 3,497 | 3,121 | 3,207 | 3,435 | 2,791 | 2,042 |
| Non Current Liabilities | 1,307 | 2,039 | 3,324 | 2,272 | 1,976 | 1,624 | 894 | 834 | 586 | 1,196 | 1,436 |
| Total Equity | 3,859 | 4,241 | 3,719 | 3,198 | 3,005 | 3,058 | 3,759 | 4,202 | 3,662 | 3,662 | 4,657 |
| Reserve & Surplus | 3,362 | 3,720 | 3,281 | 2,797 | 2,620 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 4,272 |
| Share Capital | 354 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 57 | 46 | 301 | -66 | -500 | -178 | 13 | 138 | -280 | 415 | -393 |
| Investing Activities | -222 | -106 | -684 | 635 | 93 | -147 | 1,471 | -204 | -118 | -138 | -780 |
| Operating Activities | 355 | -42 | -270 | 68 | 183 | 649 | -287 | 413 | 153 | 219 | -22 |
| Financing Activities | -76 | 193 | 1,255 | -770 | -777 | -680 | -1,171 | -71 | -315 | 334 | 409 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Nov 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 72.12 % | 69.68 % | 68.04 % | 67.13 % | 67.13 % | 65.75 % | 63.83 % | 60.36 % | 59.31 % | 58.40 % | 55.14 % | 54.93 % | 51.60 % | 51.99 % | 51.99 % | 49.09 % | 49.09 % | 49.09 % | 49.09 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.02 % | 0.00 % | 5.49 % | 5.93 % | 6.70 % | 6.62 % | 6.54 % | 6.81 % | 7.29 % |
| DIIs | 0.02 % | 0.02 % | 0.02 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.23 % | 0.22 % | 0.19 % | 0.22 % | 0.10 % | 4.83 % | 4.45 % | 5.09 % | 9.88 % | 9.82 % | 10.59 % | 11.01 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.02 % | 0.02 % | 0.02 % | 0.02 % | 0.02 % |
| Public / Retail | 21.41 % | 23.02 % | 25.24 % | 25.99 % | 24.56 % | 25.97 % | 27.42 % | 30.26 % | 31.45 % | 32.19 % | 32.89 % | 32.94 % | 29.94 % | 30.18 % | 29.02 % | 27.45 % | 27.49 % | 26.69 % | 26.05 % |
| Others | 6.46 % | 7.27 % | 6.69 % | 6.85 % | 8.28 % | 8.26 % | 8.72 % | 9.15 % | 9.02 % | 9.21 % | 8.72 % | 12.03 % | 8.13 % | 7.43 % | 7.19 % | 6.95 % | 7.04 % | 6.80 % | 6.55 % |
| No of Share Holders | 0 | 0 | 1,25,128 | 1,44,845 | 1,61,625 | 1,65,270 | 1,66,122 | 1,80,170 | 1,80,630 | 1,78,915 | 1,72,989 | 1,61,813 | 1,46,376 | 1,40,391 | 1,38,142 | 1,43,876 | 1,42,710 | 1,41,799 | 1,46,918 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Mar 2022 |  Rights | 3:10 | 08 Mar 2022 | 311.72 | 308.20 |
| 28 Jun 2024 |  Annual General Meeting | NA | 28 Jun 2024 | 514.90 | 653.75 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 1,206.50 | 1,180.80 |
| 07 Feb 2025 | Quarterly Result Announcement | NA | 07 Feb 2025 | 1,558.55 | 1,651.10 |
| 29 May 2025 | Quarterly Result Announcement | NA | 29 May 2025 | 1,320.20 | 1,337.10 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 1,667.50 | 1,519.15 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 1,828.00 | 1,519.15 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
8 days agoClosure of Trading Window8 days ago
8 days agoIntimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingsSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 21, 2025
Aug 21, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Aug 08, 2025Outcome Of The Board MeetingAug 08, 2025
Aug 08, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 08, 2025
Aug 08, 2025Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited ("The Company").Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Jul 17, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Jul 16, 2025Intimation Of Record Date For The Purpose Of 25Th Annual General Meeting (AGM) Of The Company.Jul 16, 2025
Jul 16, 2025Notice Of 26Th Annual General Meeting(AGM) Of The Company For The Financial Year 2024-25Jul 16, 2025
Jul 16, 2025Reg. 34 (1) Annual Report.Jul 16, 2025
Jul 16, 2025Reg. 34 (1) Annual Report.Jul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 11, 2025
Jul 11, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 11, 2025
Jun 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2025
May 29, 2025Board Meeting Outcome for Outcome Of The Board MeetingMay 29, 2025
May 29, 2025Board Meeting Outcome for Outcome Of The Board MeetingMay 29, 2025
May 29, 2025Outcome Of The Board MeetingMay 29, 2025
May 29, 2025Board Meeting Intimation for Pursuant To Regulation 29(1) (A) And (D) Of SEBI LODR Regulations We Wish To Inform You That A Meeting Of The Board Of Directors Of The Company Will Be Held On Thursday 29Th May 2025May 23, 2025
May 23, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
May 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Intimation For Incorporation Of A Step-Down Subsidiary Company
Apr 08, 2025
Apr 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Apr 01, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 14, 2025
Feb 14, 2025Integrated Filing (Financial)Feb 07, 2025
Feb 07, 2025Statement On Deviation Or Variation Of Funds Raised Through Qualified Institutions Placements For The Quarter Ended 31St December 2024Feb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2025
Feb 07, 2025Board Meeting Outcome for Outcome Of The Board MeetingFeb 07, 2025
Feb 07, 2025Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited
Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Jan 31, 2025Technical Indicators
RSI(14)
Neutral 49.29
ATR(14)
Less Volatile 67.80
STOCH(9,6)
Neutral 46.55
STOCH RSI(14)
Overbought 84.72
MACD(12,26)
Bullish 2.55
ADX(14)
Weak Trend 14.88
UO(9)
Bearish 49.33
ROC(12)
Downtrend And Accelerating -1.35
WillR(14)
Neutral -36.20
Mutual Fund Holdings
Bandhan Small Cap Fund Direct-Growth 
Bank of India Small Cap Fund Direct-Growth 
Samco Active Momentum Fund Direct - Growth 
ITI Small Cap Fund Direct-Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
